Biotech M&A reaches $106 billion as pharma dealmaking accelerates

Biopharma merger and acquisition activity has climbed sharply in 2026, with deals reaching $106 billion across 201 transactions so far this year, according to PitchBook data. The pace puts the sector on track for its strongest year since before the pandemic, driven by patent expirations, improving public markets, and large drugmakers seeking to strengthen their pipelines. Analysts said much of the buying is focused on smaller, strategic acquisitions rather than large takeovers. These bolton deals, often valued between $1 billion and $5 billion, can be easier to integrate and may face fewer antitrust concerns than megamergers. Companies are also under pressure to replace revenue as topselling drugs lose exclusivity in the coming years. At the same time, interest in Chinese biotech assets remains strong, with some firms using crossborder structures to bring promising products into the U.S. and Europe for development and approval.